What is erythrocytosis?
erythrocytosis is a condition in which there is an unusually high number of red blood cells or erythrocytes in circulation. What is called primary erythrocytosis can be caused by a rare bone marrow disorder known as Polycythemia vera, where bone marrow produces too many red cells. What is called secondary erythrocytosis is more common. This is usually the result of existing medical disorders, such as long -term lung disease, where tissues have been starved from oxygen and high levels of protein known as erythropoetin, stimulating red blood cell production. What is called obvious erythrocytosis may also occur where the total volume of blood plasma decreases, so that red blood cells appear to be more concentrated. Vague symptoms such as fatigue, itching, dizziness and headaches may be present. There is an increased risk of blood clots in people who have polycytmia vera, and in some cases the first sign can be a condition of thrombosis or a clot inside the blood vessel, which fromThere is a problem such as a stroke or heart attack. The United British spelling of polycythemie vera is polycythemie vera and can also be known as polycythemy rubra vera.
people who have secondary erythrocytosis can also have a greater risk of thrombosis, but it is assumed that it is smaller than those who have polycytmia vera. It is not known whether apparent erythrocytosis increases the risk of human thrombosis. Lowering the volume of blood plasma, which leads to an apparent increase in red blood cells, can be caused by alcoholism, heavy smoking or use of diuretic drugs that remove fluid from the body.
treatment of erythrocytosis depreciates the cause. Secondary forms of condition require the treatment of basic disorder and the outlook will depend on how successful it is. In the case of long -term lung disease, oxygen can help reduce the level of erythropoetin and reduce the number of red blood cells.
for the primary stAV, if the cause is a rare polycythehemical blood disease, the outlook is bad without treatment. There is a high risk of fatal stroke or heart attack within 18 months. During treatment, the outlook improves and provides an estimated life expectancy of approximately 20 years. The treatment methods include blood removal from circulation, aspirin to reduce the risk of clotting and taking drugs to reduce the number of blood cells.